Seeking Alpha

nova » Comments » BRL

  • Big Pharma’s Healthy Appetite for Acquisitions [View article]
    Why should Carl Icahn accept Bristol's offer at $60? There are no reasons for it at all.

    18 months ago, Icahn has blocked ImClone sale to Sanofi for $36. Now, Bristol offers $60.

    Icahn has a strong hand. He can tell to major ImClone shareholders: a $60-offer is not good but, in another 12-18 months, I might be able to get a new offer twice as big.

    As Imclone's shareholder, I will go for it!
    Aug 12 10:38 am |Rating: 0 0 |Link to Comment
More on BRL by nova
Comments by Ticker
AA, AAPL, ABB, ABT, ABX, ACI, ACOR, ADM, AEM, AGQ, AGU, AHBIF.PK, AIG, AKP, ALKS, ALTH, ALXN, AMAT, AMGN, AMLN, AMZN, ANDE, ANF, APOL, ARIA, ARNA, AUY, AVAV, AXP, AZN, AZO, BAC, BAL, BAYRY.PK, BBH, BBT, BCS, BDX, BHI, BIIB, BIK, BIOD, BK, BKF, BLK, BMRN, BMY, BP, BRK.A, BRK.B,
nova's
Comments Stats
569 comments
Rating: 1036 (1780 - 744 )